Indian man confesses to involvement in …
‘I would do the same’: ‘Your Honor’ star…
Home baker in Ipoh selling cakes with…
COVID-19 cases hit new record high in…
Treat yourself to a flashlight that’s not…
Amazon’s Luna cloud gaming service is now…
Busiest U.S. seaport, buried in imports…
Should I Freeze My Eggs During The…
This simple appliance that resembles a waffl…
Manchester City 1-1 West Brom: Player…
Mahindra to hike its model prices from 1…
A lawyer who dressed up as the Grim Reaper…
Singaporean trans man ‘humbled’ by support
Singapore To Open Travel Bubble As It…
Popular Yasmin Ahmad films ‘Rabun’…
Family who survived Wuhan’s coronavirus…
Mexico’s congress approves law limiting…
Madden NFL 21’s next-gen console upgrade…
Condo resale prices up 1.3% in November
Could UV-LEDs play a role in the fight…
New hawker at Newton Food Centre sells frie…
Welcome to World Class: The Shortlist -…
These are America’s most beautiful natural wonders
Indian man confesses to involvement in misappropriation of $36.1…
Messenger RNA-pioneering biotechnology company Moderna has announced that it has secured an agreement with Singapore’s Ministry of Health to supply the country with Moderna’s vaccine candidate against COVID-19, mRNA-1273.
“We continue to advance the clinical development of mRNA-1273 and the recent positive primary efficacy analysis from our Phase 3 COVE study is an encouraging step forward as we work together to address this global health emergency by delivering a vaccine to the people of Singapore and around the world,” said Moderna’s CEO Stéphane Bancel in a statement.
Data from the Phase COVE study, which involved 30,000 participants, has shown an efficacy rate against COVID-19 at 94.1% and against severe COVID-19 at 100%. “Efficacy was consistent across age, race and ethnicity, and gender demographics in the 196 observed cases of COVID-19,” Moderna noted.
The Phase 3 COVE study is continuously monitored by an independent National Institutes of Health-appointed Data Safety Monitoring Board.
The most common adverse reactions were injection site pain, erythema or redness, fatigue, myalgia, arthralgia, and headache. These adverse reactions were reported to increase “in frequency and severity in the mRNA-1273 group after the second dose.”
Moderna plans to submit data from the Phase 3 COVE study to a peer-reviewed publication, the company added.
Join MSc Webinar by Warwick on 29 Dec
ESG Access Continues to Evolve in Mexico
Singapore — YouTuber Dee Kosh, who was alleged some months ago to have solicited sexual favours from minors, was thrust under the spotlight again at the weekend when photos surfaced online of him serving a Corrective Work Order (CWO). However, in a display of camaraderie on Instagram on Monday (Dec 14), fellow YouTuber Ryan Tan, […]
In light of Christmas’ true season of giving, do go one step beyond gifting presents to your loved ones by giving back to the community. The post Plant Trees And Donate Coins: How Shopee Makes It Fun For You To Give Back This X’mas appeared first on Vulcan Post.
PM Lee has listed Moderna, Pfizer-BioNTech, and Sinovac as some of the “promising candidates” for COVID-19 vaccines. The post What Singaporeans Need To Know About COVID-19 Vaccines: How Safe And Effective Is It? appeared first on Vulcan Post.
Singapore—The Expert Committee that advised the Government on the Covid-19 vaccine strategy has mentioned three groups who will not be given vaccine doses: women who are pregnant, children younger than 16 years old, and people who are immunocompromised or have an impaired immune system. Prime Minister Lee Hsien Loong announced on Monday (Dec 14) that […]
